Royalty Pharma PLC
NASDAQ:RPRX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.28
40.5542
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
RPRX
stock under the Base Case scenario is
64.62
USD.
Compared to the current market price of 38.26 USD,
Royalty Pharma PLC
is
Undervalued by 41%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Royalty Pharma PLC.
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Royalty Pharma’s core revenue streams are highly exposed to patent cliffs on its top-selling therapies, creating potential for steep revenue declines if pipeline replacements fail to materialize in time.
Increasing competition from rival royalty aggregators and private equity firms could drive up the cost of acquiring new royalty streams, limiting Royalty Pharma’s ability to secure favorable deals.
Regulatory setbacks—such as unexpectedly negative clinical trial results or pricing pressure for key drugs—could reduce the attractiveness of the underlying royalty streams and weaken long-term returns.
Royalty Pharma’s diversified portfolio of royalties across multiple blockbuster therapies shields it from the volatility typically associated with single-drug exposure, supporting robust cash flows.
The company’s strong track record of securing royalty deals with leading biopharma innovators positions it as a partner of choice in the industry, enabling it to access lucrative late-stage pipelines.
Its ability to selectively deploy capital into promising clinical programs allows Royalty Pharma to grow royalties and expand its pipeline without the heavy R&D costs that conventional pharma players must shoulder.
Revenue & Expenses Breakdown
Royalty Pharma PLC
Balance Sheet Decomposition
Royalty Pharma PLC
| Current Assets | 1.8B |
| Cash & Short-Term Investments | 1.8B |
| Receivables | 28.9m |
| Other Current Assets | 5.5m |
| Non-Current Assets | 17.5B |
| Long-Term Investments | 16.5B |
| PP&E | 19.8m |
| Intangibles | 924.6m |
| Other Non-Current Assets | 66.8m |
| Current Liabilities | 530.8m |
| Accounts Payable | 41.4m |
| Accrued Liabilities | 29m |
| Other Current Liabilities | 460.3m |
| Non-Current Liabilities | 12.4B |
| Long-Term Debt | 8.6B |
| Other Non-Current Liabilities | 3.8B |
Free Cash Flow Analysis
Royalty Pharma PLC
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Royalty Pharma PLC
|
Revenue
|
2.3B
USD
|
|
Operating Expenses
|
-817.2m
USD
|
|
Operating Income
|
1.5B
USD
|
|
Other Expenses
|
-767.7m
USD
|
|
Net Income
|
765m
USD
|
RPRX Profitability Score
Profitability Due Diligence
Royalty Pharma PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Royalty Pharma PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
RPRX Solvency Score
Solvency Due Diligence
Royalty Pharma PLC's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Royalty Pharma PLC's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RPRX Price Targets Summary
Royalty Pharma PLC
According to Wall Street analysts, the average 1-year price target for
RPRX
is 46 USD
with a low forecast of 35.02 USD and a high forecast of 58.8 USD.
Dividends
Current shareholder yield for
RPRX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
RPRX
stock under the Base Case scenario is
64.62
USD.
Compared to the current market price of 38.26 USD,
Royalty Pharma PLC
is
Undervalued by 41%.